IDENTIFICATION OF KEY TARGET GENES AND
PATHWAY ANALYSIS IN NONALCOHOLIC FATTY LIVER
DISEASE VIA INTEGRATED BIOINFORMATICS ANALYSIS
Chen X.1, Zhang L.2, Wang Y.1, Li R.1, Yang M.1, Gao L.3*
*Corresponding Author: Lei Gao, MD, College of Basic Medicine, Changchun University of Chinese
Medicine, 1035 Boshuo, Road, Jingyue District, Changchun City, Jilin Province, 130117, China;
Tel:+ 86-431-8604 5309, Email: gaolei790708@163.com
page: 10
download article in pdf format
|
|
Abstract
Purpose: This study aimed at exploring the mechanisms
underlying nonalcoholic fatty liver disease (NAFLD)
and developing new diagnostic biomarkers for nonalcoholic
steatohepatitis (NASH). Methods: The microarray
dataset GES83452 was downloaded from the NCBI-GEO
database, and the differentially expressed RNAs (DERs)
were screened between the NAFLD and non-NAFLD
samples of the baseline and 1-year follow-up time point
group based on the Limma package. Results: A total of
561 DERs (268 downregulated and 293 upregulated) were
screened in the baseline time point group, and 1163 DERs
(522 downregulated and 641 upregulated) were screened
in the 1-year follow-up time point group. A total of 74
lncRNA–miRNA pairs and 523 miRNA–mRNA pairs were
obtained in order to construct a lncRNA–miRNA–mRNA
regulatory network. Subsequently, functional enrichment
analysis revealed 28 GO and 9 KEGG pathways in the
ceRNA regulatory network. LEPR and CXCL10 are involved
in the Cytokine–cytokine receptor interaction (P =
1.86E-02), and the FOXO1 is involved in both the insulin
signaling pathway (P = 1.79E-02) and the pathways in
cancer (P = 2.87E-02). Conclusion: LEPR, CXCL10, and
FOXO1 were the characteristic target genes for NAFLD.
|
|
|
|
 |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
